MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) VP Jeffrey Stuart Peters sold 31,105 shares of MacroGenics stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $4.15, for a total transaction of $129,085.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
MacroGenics Price Performance
Shares of MacroGenics stock traded down $0.10 on Thursday, hitting $4.07. 381,814 shares of the company’s stock traded hands, compared to its average volume of 1,043,859. The firm’s 50-day moving average price is $4.24 and its two-hundred day moving average price is $3.44. The stock has a market capitalization of $259.26 million, a PE ratio of -18.50 and a beta of 1.20. MacroGenics, Inc. has a one year low of $1.29 and a one year high of $5.08.
MacroGenics (NASDAQ:MGNX – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.39. The business had revenue of $32.83 million during the quarter, compared to analysts’ expectations of $59.14 million. MacroGenics had a negative return on equity of 109.26% and a negative net margin of 8.70%. On average, analysts forecast that MacroGenics, Inc. will post -1.48 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
View Our Latest Research Report on MacroGenics
Institutional Investors Weigh In On MacroGenics
A number of hedge funds and other institutional investors have recently bought and sold shares of MGNX. Legal & General Group Plc bought a new stake in MacroGenics in the 2nd quarter valued at approximately $28,000. Seven Fleet Capital Management LP bought a new position in shares of MacroGenics during the 1st quarter worth approximately $39,000. Two Sigma Securities LLC bought a new position in shares of MacroGenics during the 2nd quarter worth approximately $63,000. R Squared Ltd acquired a new stake in shares of MacroGenics in the fourth quarter valued at approximately $26,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of MacroGenics in the second quarter valued at approximately $82,000. Institutional investors and hedge funds own 96.89% of the company’s stock.
About MacroGenics
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.
Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.
Featured Stories
- Five stocks we like better than MacroGenics
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.
